PMID- 33306218 OWN - NLM STAT- MEDLINE DCOM- 20210317 LR - 20210317 IS - 1096-8652 (Electronic) IS - 0361-8609 (Linking) VI - 96 IP - 3 DP - 2021 Mar 1 TI - CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. PG - 312-319 LID - 10.1002/ajh.26069 [doi] AB - The identification of genetic risk subgroups of T-cell acute lymphoblastic leukemia (T-ALL) may provide evidence for risk stratification and individualized treatment. We investigated the characteristics and prognostic value of tumor suppressor gene CDKN2A deletions in 101 patients with T-ALL. The CDKN2A deletion was present in 23% (23/101) of T-ALL by fluorescence in situ hybridization (FISH). The most common type of CDKN2A deletion was homozygous deletion (70%, 16/23). A lower frequency of CDKN2A deletion was found in patients with early T-cell precursor (ETP) ALL than in patients with non-ETP-ALL (10.4% vs 34.0%; P = .008). Deletion of CDKN2A was significantly associated with younger age (P = .001), higher white blood cell (WBC) count (P < .001) and higher lactate dehydrogenase (LDH) level (P = .002). Patients with CDKN2A deletion had lower 2-year overall survival (OS) and event-free survival (EFS) rates than patients without CDKN2A deletion (2-year OS: 18.6% +/- 8.9% vs 47.4% +/- 6.2%, P = .032; EFS: 16.4 +/- 8.3 vs 38.6 +/- 5.9%, P = .022). In multivariable analysis, CDKN2A deletion was an independent adverse prognostic factor for OS (P = .016). In conclusion, adult T-ALL patients with CDKN2A deletion had a poor prognosis, and these patients might benefit from intensive chemotherapy or allogeneic hematopoietic stem-cell transplantation. CI - (c) 2020 Wiley Periodicals LLC. FAU - Wang, Huan-Ping AU - Wang HP AUID- ORCID: 0000-0003-4080-3329 AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Zhou, Yi-Le AU - Zhou YL AUID- ORCID: 0000-0002-9216-5261 AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Huang, Xin AU - Huang X AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Zhang, Yi AU - Zhang Y AUID- ORCID: 0000-0003-3625-2288 AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Qian, Jie-Jing AU - Qian JJ AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Li, Jian-Hu AU - Li JH AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Li, Xue-Ying AU - Li XY AUID- ORCID: 0000-0002-9609-1984 AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Li, Chen-Ying AU - Li CY AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Lou, Yin-Jun AU - Lou YJ AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Mai, Wen-Yuan AU - Mai WY AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Meng, Hai-Tao AU - Meng HT AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Yu, Wen-Juan AU - Yu WJ AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Tong, Hong-Yan AU - Tong HY AUID- ORCID: 0000-0001-5603-4160 AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Jin, Jie AU - Jin J AUID- ORCID: 0000-0002-8166-9915 AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Zhu, Hong-Hu AU - Zhu HH AUID- ORCID: 0000-0003-2343-0436 AD - Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201224 PL - United States TA - Am J Hematol JT - American journal of hematology JID - 7610369 RN - 0 (CDKN2A protein, human) RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - 0 (DNA, Neoplasm) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Allografts MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - China/epidemiology MH - Combined Modality Therapy MH - Cyclin-Dependent Kinase Inhibitor p16/*deficiency MH - DNA Mutational Analysis MH - DNA, Neoplasm/genetics MH - Female MH - *Gene Deletion MH - *Genes, p16 MH - Hematopoietic Stem Cell Transplantation MH - High-Throughput Nucleotide Sequencing MH - Humans MH - In Situ Hybridization, Fluorescence MH - Male MH - Middle Aged MH - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/*genetics/mortality/therapy MH - Prognosis MH - Treatment Outcome MH - Young Adult EDAT- 2020/12/12 06:00 MHDA- 2021/03/18 06:00 CRDT- 2020/12/11 12:09 PHST- 2020/08/25 00:00 [received] PHST- 2020/12/06 00:00 [revised] PHST- 2020/12/08 00:00 [accepted] PHST- 2020/12/12 06:00 [pubmed] PHST- 2021/03/18 06:00 [medline] PHST- 2020/12/11 12:09 [entrez] AID - 10.1002/ajh.26069 [doi] PST - ppublish SO - Am J Hematol. 2021 Mar 1;96(3):312-319. doi: 10.1002/ajh.26069. Epub 2020 Dec 24.